Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Evidence is presented that at least one of the antigens of human ovarian cancer tissue which appeared to be tumor-associated in immunodiffusion and immunoelectrophoresis experiments actually represents a quantitative rather than a qualitative difference between normal and malignant tissue. A glucoprotein band (Rf equals 0.01) believed to contain at least one tumor-associated antigen was isolated by disc-gel electrophoresis with 5.6 per cent SDS-acrylamide and was used to immunize rabbits. Immunodiffusion and immunoelectrophoresis experiments with the resulting antiserum indicated that the glycoprotein band contained two antigens, one which was present in normal extracts at a concentration approximately one tenth of that in tumor extracts and another which was detectable only in tumor tissue. The tenfold difference between normal and tumor tissue was confirmed by studies of the appearance and disappearance of the glycoprotein band when acrylamide gel electrophoresis was performed on varying amounts of normal and tumor extracts.
 ...
PMID:Quantitation of antigens in normal and malignant ovarian tissue. 118 Feb 93

Peripheral blood lymphocytes from 11 patients with ovarian carcinoma were incubated several times with autologous tumor extract as well as phytohemagglutinin (PHA) at different concentrations. Lymphocytes from 10 normal, healthy, age-matched females were also studied similarly. Tritiated thymidine incorporation into DNA of transformed lymphocytes was measured. No significant response was obtained with lymphocytes from ovarian cancer patients or normal individuals in the presence of tumor extracts. Of 6 tumor extracts tested, 5 did not have any cytotoxic effect on autologous or on homologous normal healthy lymphocytes. Hence, with this test system employed, no evidence for a cell-mediated immunity to autologous tumor in ovarian cancer patients was observed. PHA, on the other hand, induced vigorous blastogenic response in several ovarian cancer patient's lymphocytes, as well as in all normal healthy lymphocytes, indicating no inherent defect in the T-lymphocyte system of ovarian cancer patients. Only 2 of the patients, when tested for delayed hypersensitivity reaction against a battery of recall antigens and keyhole limpet hematocyanin, were completely anergic. None of the patients responded when skin tested with their own tumor extracts.
 ...
PMID:Lymphocyte response to autologous tumor antigen(s) and phytohemagglutinin in ovarian cancer patients. 118 82

Peritoneal effusions of patients with ovarian cancer contain sizable amounts of free and complexed immunoglobulins. By means of salt precipitation procedures, antibodies were recovered that after purification and concentration displayed a high degree of specificity against ovarian carcinoma cells. In indirect immunofluorescence, immunoglobulins recovered from seven different peritoneal effusions showed bright cytoplasmic staining with tissue cultures and fresh suspensions of ovarian carcinoma cells but not of normal ovaries or non-ovarian tumors. Immunoglobulins isolated from fluids of benign ovarian cysts or from effusions of non-ovarian tumors were negative in immunofluorescence tests. Autologous antibodies recovered from peritoneal effusions will be hopefully utilized in sensitive radioimmunoassay tests that are greatly needed for the early detection of ovarian cancer, the leading cause of death from gynecologic neoplasia.
 ...
PMID:Isolation of tumor-specific antibodies from effusions of ovarian carcinomas. 118 43

From 1960 to 1972, 276 out of 330 cases of ovarian cancer were treated by different techniques of postoperative radiation therapy; 54 advanced cases underwent prospective chemotherapy. Radiogold intraabdominally administered (190 to 300 mCi), telecobalt (5000 rd) or the combination of radiogold and telecobalt was chosen for postoperative radiation therapy. Cyclophosphamide (Endoxan), prednisolone, and gestagenes (Prothil) were given as a long-term chemotherapy. The most successful technique of radiation therapy is confronted with long-term chemotherapy after three years (five years) of survival: Stage I a, b, c: Radiogold = 91.7% (66.7%), chemotherapy (only I c) = 100%. Stage II a, b: Radiogold + telecobalt = 47% (35%), chemotherapy = 85%. Stage III: Radiogold + telecobalt = 25% (0%), chemotherapy = 52%. Stage IV: Radiotherapy = 0%, chemotherapy = 25%. The absolute five-year survival without chemotherapy amounted to 23%. The mortality curve under chemotherapy shows a four-year survival rate of 88%, if tumor cells had been detected microscopically (ascites, omentum), but of only 30% after macroscopical verification of the tumor. Therefore, the maximally possible partial resection of the tumor is recommended in inoperable stages before the beginning of chemotherapy. "Prophylactic" long-term chemotherapy following macroscopically complete surgical treatment is recommended, whenever microscopical spread of tumor cells appears to be possible. In inoperable stages, chemotherapy ought to be applied prior to radiation therapy. In stages I a, b, c, and II a, postoperative irradiation with radiogold (100 mCi) and in stage II b additionally radiation teletherapy of the pelvis (6000 rd) is recommended.
 ...
PMID:[Comparison of the results of radio gold therapy, cobalt 60 teletherapy and chemotherapy in 330 ovarian neoplasms]. 120 71

The effect of tumor bulk resection on survival was studied in 102 patients with stages II and III ovarian cancer. A multiple linear regression equation provuded both simultenaous control of multiple confounding variables and an assessment of these variables as independent predictors of survival. The most important factors were the histologic grade of the tumor and the size of the largest residual tumor mass after operation. Survival time was uniformly poor if the diameter of the largest residual tumor mass exceeded 1.5 cm irrespective of total tumor volume (mean=12.7 months, SE=1.6 mo). Survival time was inversely proportional to residual mass size under 1.6 cm, and surgery improved survival relative to reduction in mass size below this limit. Extensive resections of tumor bulk with failure to remove all masses greater than 1.5 cm in diameter did not influence survival. Surgery provides optimum benefit when all gross tumor can be excised safely.
 ...
PMID:Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. 123 24

Different techniques for whole abdominal irradiation after tumor removal from patients with ovarian cancer are discussed. The concept of subclinical disease is stressed.
 ...
PMID:Ovarian cancer, with special regard to types of radiotherapy. 123 29

The ultrastructure of the major histologic types of ovarian carcinoma was investigated as part of a multilateral study of this tumor. The nuclear and nucleolar changes in size, shape, and structure correlated well with the degree of malignancy and tumor grading. Cytoplasmic organelles and intercellular junctions were abundant and fairly well differentiated even in ovarian carcinomas of higher grade and stage. Active processes of synthesis and secretion taking place in most of these tumors were suggested by the presence of a richly granulated endoplasmic reticulum, dilated cisternae, and numerous secretory granules. Seventy-eight different ovarian carcinomas of all histologic types were cultured in vitro for periods of up to 300 days, and their morphology in light and electron microscopy was compared to that of the original tumors. The cultures displayed a consistent pattern of growth which led to the conclusion that ovarian cancer cells in vitro preserve their salient features and are representative of the tumors of origin. Heterologous antisera raised with pooled extracts of various types of ovarian carcinomas reacted specifically in immunodiffusion and immunofluorescence tests only with ovarian carcinomas and not with normal ovaries, benigh ovarian tumors, and nonovarian malignant neoplasms, indicating the presence of a cross-reacting specific antigen for ovarian carcinomas. In other studies, autologous antibodies were isolated from antigen-antibody complexes recovered from peritoneal effusions of patients with ovarian carcinomas. These antibodies displayed a high degree of specificity against ovarian carcinoma cells when tested in immunofluorescence assays.
 ...
PMID:Electron microscopy, tissue culture,and immunology of ovarian carcinoma. 123 35

Cancer of the ovary is the leading cause of death from gynecologic cancer. The constant challenge presented by ovarian cancer is that about 11,000 women die from ovarian cancer each year and the results in 1974 are no better than have been achieved in the previous two decades. Standard practice of treatment for truly invasive common epithelial ovarian cancer includes total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, and post-surgical insertion of tubes and administration of P32 (if the disease is of limited extent). Although it is occasionally necessary to resect isolated segments of bowel, exenterative or ultraradical surgery in the management of ovarian cancer is not usually chosen because of the natural history of the disease. However, aggressive surgery is indicated not so much because it is curative, but because it potentiates other forms of treatment. All stages I through IV are treated surgically, to remove as much tumor as possible without running a risk of a gastrointestinal or genitourinary fistula. Radiation therapy has been utilized in addition to the surgical therapy in stage IV to control supraclavicular and/or inguinal node involvement. Single agent alkylating chemotherapy is chosen for the treatment of common epithelial ovarian cancers. Combination chemotherapy does not produce better results at this time, except in the treatment of embryonal tumors. The treatment of the common epithelial tumors by stage is outlined. The treatment of germ cell tumors, gonadal stromal tumors, ovarian tumors in childhood, ovarian tumors in pregnancy, as well as tumors not specific for the ovary, will also be discussed.
 ...
PMID:Current status of the treatment of gynecologic cancer by site: ovary. 127 13

To investigate the effects of combination chemotherapy on ovarian cancer in vitro, we observed the sensitivity of tumors to different drugs by incorporation assay of tritium thymidine (3H-TdR). The results revealed that the drugs and their sensitive degrees varied from tumor to tumor. Whether the combination of the drugs is synergism or sometimes only enhances toxicity depends on the difference of individuals. We suggest that in vitro anti-cancer drug sensitivity test could be applied in selection or determination of chemotherapy protocol.
 ...
PMID:[Effects of combination chemotherapy of ovarian cancer in vitro]. 128 40

In a prospective study, CA 125 and CA 19.9 serum levels were measured in 229 patients with ovarian cancer [121 with active disease, 108 in complete remission (CR)], and in 20 patients with other malignancies. Abnormal levels of CA 125 were found in 90% of patients with active ovarian cancer, in 1.8% of those in CR and in 38% of cases with other malignancies. Abnormal CA 19.9 serum levels were found in 36, 9 and 48% of these groups, respectively. Serum levels of both tumor markers were related to tumor stage and histological type. The highest levels of CA 125 were found in serous adenocarcinoma and the lowest in the mucinous type (p < 0.0001). In contrast, significantly higher CA 19.9 values were found in mucinous carcinoma than in other histologies (p < 0.0001). CA 125 and CA 19.9 were useful for monitoring disease activity in 88.3 and 32%, respectively, while one or other tumor marker was useful in 92% of patients. At the time of the second-look operation, abnormal CA 125 serum levels were found in 32% (6/19) of patients with active disease and in none of those with CR (0/38). CA 125 sensitivity was 83% (5/6) in those patients with residual tumor > 2 cm and in 8% (1/13) in those with tumor < 2 cm. CA 19.9 values were abnormally high in 16% of cases with persistent disease and in 11% of CR patients. In conclusion, our results confirm that CA 125 is a useful marker in ovarian carcinoma. CA 19.9 improves the results obtained with CA 125 alone only in mucinous adenocarcinomas.
Tumour Biol 1992
PMID:A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. 129 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>